Otsuka will acquire Transcend Therapeutics in a deal worth up to $1.225 billion to advance TSND-201, a rapid-acting investigational therapy for PTSD that showed positive Phase 2 IMPACT-1 trial results.
Written By: Chikkula Pavan Kumar, PharmD
Reviewed By: Pharmacally Editorial Team
Otsuka Pharmaceutical has agreed to acquire Transcend Therapeutics, a clinical-stage biotechnology company developing rapid-acting treatments for neuropsychiatric disorders, as the Japanese drugmaker expands its neuroscience pipeline. The transaction centers on TSND-201 (methylone), an investigational therapy being developed for post-traumatic stress disorder (PTSD).
TSND-201 is a rapid-acting neuroplastogen, a class of compounds designed to promote neural plasticity in the brain. Altered neuroplasticity is believed to play a key role in the onset and persistence of PTSD symptoms by affecting fear processing, memory formation, and emotional regulation.
The therapy acts on monoamine transporters for serotonin, norepinephrine, and dopamine, increasing neurotransmitter levels in the synaptic cleft and promoting neural circuit remodeling. TSND-201 does not activate the serotonin 5-HT2A receptor, meaning it is considered non-hallucinogenic, differentiating it from certain psychedelic-inspired psychiatric therapies.
Clinical Evidence Supporting TSND-201
The Phase 2 IMPACT-1 trial (NCT05741710) was a randomized, double-blind, placebo-controlled study that evaluated TSND-201 in adults with severe PTSD across 16 sites in the United States, the United Kingdom, and Ireland.
The study enrolled 65 patients with severe PTSD, defined by a CAPS-5 total severity score of 35 or higher. Participants received oral TSND-201 or placebo once weekly for four weeks, followed by an additional six-week follow-up period.
The trial met its primary endpoint, with patients treated with TSND-201 demonstrating significant reductions in CAPS-5 total severity scores from baseline through Day 64 compared with placebo.
Notably, statistically significant improvements in PTSD symptoms were observed from Day 10 onward, highlighting the therapy’s rapid onset of clinical activity.
TSND-201 was generally well tolerated, with the most common treatment-emergent adverse events including headache, decreased appetite, nausea, dizziness, increased blood pressure, dry mouth, and insomnia. These events were typically transient and resolved within one day of dosing. Study findings were published in JAMA Psychiatry in February 2026.
Based on these results, TSND-201 received Breakthrough Therapy designation from the U.S. Food and Drug Administration in July 2025, and patient recruitment for a Phase 3 trial is currently underway in the United States following regulatory discussions on the pivotal study design.
Addressing a Major Unmet Need in PTSD
PTSD is a serious mental health condition that can develop after exposure to traumatic or life-threatening events and is characterized by symptoms such as flashbacks, nightmares, severe anxiety, and intrusive memories.
More than 13 million people in the United States are estimated to live with PTSD each year, yet treatment options remain limited. Only two medications sertraline and paroxetine are currently approved for the condition, and no new pharmacological treatments have been introduced in over two decades, highlighting the need for novel therapeutic approaches.
Deal Terms and Strategic Rationale
Under the acquisition agreement, Otsuka will pay $700 million upfront to Transcend shareholders upon closing and up to $525 million in additional milestone payments tied to future sales performance, for a total potential deal value of $1.225 billion. The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions.
Founded in 2021, Transcend is also advancing novel prodrug versions of TSND-201 designed to optimize efficacy, safety, and tolerability. A development candidate has been selected and is currently undergoing non-clinical studies ahead of a planned investigational new drug application.
Otsuka has long focused on psychiatric and neurological disorders, including schizophrenia, bipolar disorder, and depression. By adding TSND-201 an investigational asset with a mechanism distinct from its existing portfolio, the company aims to accelerate the development of next-generation treatments for PTSD and other neuropsychiatric conditions
Reference
Otsuka Pharmaceutical to Acquire Transcend Therapeutics – Expands Otsuka portfolio in psychiatric and neurological fields and aims to accelerate development of Transcend’s portfolio, including the TSND-201 program for post-traumatic stress disorder (PTSD), 27 March 2026, https://www.otsuka.co.jp/en/company/newsreleases/2026/20260327_2.html
Otsuka Pharmaceutical to Acquire Transcend Therapeutics, 27 March 2026, https://transcendtherapeutics.com/otsuka-pharmaceutical-to-acquire-transcend-therapeutics/
A Study to Assess the Use of Methylone in the Treatment of PTSD (IMPACT-1), ClinicalTrials.gov ID NCT05741710, https://clinicaltrials.gov/study/NCT0574171
About the Writer
Chikkula Pavan Kumar, PharmD is a Doctor of Pharmacy with a keen interest in clinical pharmacy, pharmacovigilance, and evidence-based practice. In his words, he is passionate about patient safety and translating complex medical information into clear, research-driven communication.
